Clinical trials: Apixaban, completed
Coagulation Disorder
Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects
A single centre, double-blind, randomized, parallel group, placebo-controlled study in healthy subjects conducted in two parts: Part 1: Single ascending doses in healthy subjects aged 18 to 49 years to assess safety…
- Trial name
- NCT05152420
- Testing
- VMX-C001, Apixaban, Rivaroxaban
- Where
- Netherlands
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- VarmX B.V.
Anticoagulation
Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery
The primary purpose of this protocol is to evaluate the safety of Apixaban in prophylaxis of Venous Thromboembolism (VTE) in Indian patients undergoing elective total knee or hip replacement
- Trial name
- NCT01884337
- Testing
- Apixaban
- Where
- 20 sites in India
- Volunteers
- 557 people
- Sponsor
- Bristol-Myers Squibb
Thrombosis
Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers
To estimate the pharmacokinetics of apixaban when administered as three different modified release formulation tablets relative to that when apixaban is administered as an immediate release tablet
- Trial name
- NCT00914641
- Testing
- Apixaban IR, Apixaban MR1, Apixaban MR2
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Severe Bleeding, Urgent Surgery
Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists
Patients treated with Vitamin K antagonists (VKA) or direct oral anticoagulants as Rivaroxaban, Apixaban, Edoxaban or Dabigatran, who experience severe bleeding and/or need urgent interventions/operations that cannot wait are…
- Trial name
- RADOA (NCT01722786)
- Where
- Germany
- Volunteers
- 272 people
- Sponsor
- Cardioangiologisches Centrum Bethanien
Myeloproliferative Neoplasm
Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms
Patients with myeloproliferative neoplasms (MPN) are predisposed to have an increased thrombotic and hemorrhagic risk and, in this context, the use of newly approved direct oral anticoagulants (DOACs) may have improved bleeding…
- Trial name
- MPN-DOACs (NCT04192916)
- Testing
- DOACs
- Where
- 18 sites in United States, Canada and 5 more
- Volunteers
- 442 people
- Sponsor
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Venous Thromboembolism
Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer
Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end-point (PROBE) study
- Trial name
- CARAVAGGIO (NCT03045406)
- Testing
- Apixaban, Dalteparin
- Where
- 127 sites in United States, Belgium and 9 more
- Volunteers
- 1,170 people
- Sponsor
- Fadoi Foundation, Italy
NonValvular Atrial Fibrillation
Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation
The primary objectives of this study are: To estimate the incidence rate of unexpected adverse events To characterize the bleeding events and assess risk factors of bleeding To identify ancillary baseline variables that may also…
- Trial name
- NCT02007655
- Testing
- Eliquis
- Where
- Japan
- Volunteers
- 6,372 people
- Sponsor
- Bristol-Myers Squibb
Anticoagulants and Bleeding Disorders
DAPHNE Study: Direct Anticoagulant PHarmacogeNEtic
New/direct oral anticoagulants (NOAC/DOAC), like apixaban and rivaroxaban, are an interesting alternative to unfractionated or low molecular weight heparin relayed by oral anti-vitamin K anticoagulants (VKA) for the treatment of…
- Trial name
- DAPHNE (NCT03112525)
- Testing
- CYP3A4/5 and P-gp phenotyping, CYP3A4/5 and P-gp genotyping
- Where
- Switzerland
- Volunteers
- 300 people
- Sponsor
- University Hospital, Geneva
Atrial Fibrillation
Burden of Ischemic Stroke and Intake of Oral Anticoagulants in Patients With Atrial Fibrillation in the UK Primary Care
This study will characterize patients with ischemic stroke, a condition which occurs when a vessel supplying blood to the brain is obstructed, and a subpopulation of patients with irregular and often rapid heart rate (atrial…
- Trial name
- BEST-AF (NCT04099238)
- Testing
- Oral anticoagulant
- Where
- United Kingdom
- Volunteers
- 3,739 people
- Sponsor
- Bayer
Venous Thrombosis, Pulmonary Embolism
BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery
The purpose of this study is to learn if BMS-562247 can prevent blood clots in the legs and lungs in men and women following unilateral total knee replacement surgery. The safety of this treatment will also be studied.
- Trial name
- NCT00097357
- Testing
- Apixaban, Enoxaparin, Warfarin
- Where
- 147 sites in United States, Argentina and 7 more
- Volunteers
- 1,238 people
- Sponsor
- Bristol-Myers Squibb
Venous Thromboembolism
Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Trial name
- NCT04736719
- Testing
- Apixaban, Warfarin
- Where
- United States
- Volunteers
- 19,002 people
- Sponsor
- Brigham and Women's Hospital
Pleural Effusion, Thoracic Effusion
The Safety of Thoracentesis, Tunneled Pleural Catheter, and Chest Tubes in Patients Taking Novel Oral Anti-Coagulants
To assess risks of bleeding in those individuals receiving Novel Oral Anti-Coagulant (NOAC) medications, admitted to the hospital and require thoracentesis, chest tube or tunneled pleural catheter placement.
- Trial name
- NCT03535883
- Testing
- Novel Oral Anti-Coagulants
- Where
- United States
- Volunteers
- 590 people
- Sponsor
- Yale University
Venous Thromboembolism (VTE)
A Study of Hospital Healthcare Use and Cost in Patients in the Hospital With a Venous Thromboembolism (VTE) Treated With Apixaban or Warfarin in the US
A study involving real-world database analysis to evaluate the hospital healthcare utilization and costs, and all-cause, major bleeding-, clinically relevant bleeding-, any bleeding-, and venous thromboembolism (VTE)-related…
- Trial name
- NCT04141228
- Where
- United States
- Volunteers
- 28,000 people
- Sponsor
- Bristol-Myers Squibb
Healthy
PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers
This study aims to evaluate the effects of combination therapy of tegoprazan and novel oral anticoagulants (NOACs) on the pharmacokinetic and pharmacodynamic properties of NOACs in healthy adults.
- Trial name
- NCT05723510
- Testing
- Tegoprazan 50mg, Edoxaban 60mg, Apixaban 5mg
- Where
- South Korea
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Venous Thrombosis, Neoplasms
Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis
The goal of the pilot study is to determine if a multicenter prospective cohort study of cancer patients with blood clots associated with catheters is feasible.
- Trial name
- NCT01999179
- Testing
- Heparin, Low-Molecular-Weight, or direct oral anticoagulants
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Medical College of Wisconsin
Anticoagulation
A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects
The purpose of this study is to assess the effect of two 4-Factor PCC formulations on Apixaban pharmacodynamics in healthy adult subjects.
- Trial name
- NCT02074358
- Testing
- Apixaban, Cofact (4-Factor PCC), Beriplex P/N (4-Factor PCC)
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Intracranial Hemorrhages, Intracranial Hemorrhage, Hypertensive
Start or STop Anticoagulants Randomised Trial (SoSTART)
Primary research question: For adults surviving spontaneous (non-traumatic) symptomatic intracranial haemorrhage with persistent/paroxysmal atrial fibrillation/flutter (AF), does starting full treatment dose oral anticoagulation…
- Conditions
- Intracranial Hemorrhages, Intracranial Hemorrhage, Hypertensive, Subarachnoid Hemorrhage, Subdural Hematoma
- Trial name
- SoSTART (NCT03153150)
- Testing
- Apixaban, Rivaroxaban, Edoxaban
- Where
- 67 sites in United Kingdom
- Volunteers
- 203 people
- Sponsor
- University of Edinburgh
Deep Vein Thrombosis, Pulmonary Embolism
Early Post-Marketing Study of ELIQUIS (Apixaban) in Mexico
The primary objective of the study is to report adverse events of on-treatment AEs by the treating physicians during a specified 24-month study period in patients with venous thromboembolism at the sentinel site(s) for the…
- Trial name
- NCT02345343
- Testing
- Apixaban
- Where
- Mexico
- Volunteers
- 100 people
- Sponsor
- Bristol-Myers Squibb
Symptomatic Aortic Stenosis, Eligible for Transcatheter Aortic Valve Replacement
Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis
ATLANTIS is a multicenter, phase IIIb, prospective, open-label, randomized trial. The objective of this study is to demonstrate superiority of a strategy of anticoagulation with apixaban (Anti-Xa Group) as compared to the current…
- Trial name
- ATLANTIS (NCT02664649)
- Testing
- Apixaban, Standard of care
- Where
- 4 sites in France, Germany and 2 more
- Volunteers
- 1,510 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Atrial Fibrillation, Stroke
Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation
This study aims to determine if treatment with apixaban, compared with aspirin, will reduce the risk of ischemic stroke and systemic embolism in patients with device-detected sub-clinical atrial fibrillation and additional risk…
- Trial name
- ARTESiA (NCT01938248)
- Testing
- Apixaban, aspirin
- Where
- 130 sites in United States, Belgium and 11 more
- Volunteers
- 4,012 people
- Sponsor
- Population Health Research Institute